• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 10Efficacy outcomes of sitagliptin monotherapy compared with an active agent

Author, yearChange in HbA1c from baseline at (%)Change in weight from baseline at (kg)
S25/50PBO/GlipS25/50PBO/Glip
54 weeks54 weeks
Chan, 2008a 37−0.7−0.8−0.90
S100GlipS100Glip
12 weeks12 weeks
Scott, 200730−0.54d−0.76+0.4+0.9
S100M1M2S100M1M2
24 weeks24 weeks
Goldstein, 200731−0.66−0.82−1.130−0.9−1.1
54 weeks54 weeks
Williams-Herman, 200932b−0.8−1.0−1.30.6−1.0−1.5
104 weeks104 weeks
Williams-Herman, 201033c−1.2−1.1−1.3+0.5−0.8−2.8
S100M2S100M2
24 weeks24 weeks
Aschner, 201038−0.43−0.57−0.6−1.9

Abbreviations: Glip, glipizide; M1, metformin 1000 mg/day; M2, metformin 2000 mg/day; PBO/Glip, placebo added to glipizide; S25/50, sitagliptin 25mg or 50mg daily; S100, sitagliptin 100 mg daily.

a

Glipizide added to placebo group after 12 weeks for remaining 42 weeks. Sitagliptin dose determined by renal function. Patients could be on insulin, number not reported.

b

Extension of Goldstein, 2007 to 54 weeks.

c

Extension of Goldstein, 2007 to 104 weeks.

d

P <0.001 for between group comparison.

Glipizide added to placebo group after 12 weeks for remaining 42 weeks. Sitagliptin dose determined by renal function. Patients could be on insulin, number not reported.

Extension of Goldstein, 2007 to 54 weeks.

Extension of Goldstein, 2007 to 104 weeks.

P <0.001 for between group comparison.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.